|
Squamous cell carcinoma of esophagus
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Mutations in TP53 and CDKN2A and copy number alterations in 11q (contains CCND1), 3q (contains SOX2), 2q (contains NFE2L2), and 9p (contains CDKN2A) were considered to be trunk variants; these were dominant mutations detected at high frequencies in clones of paired IEN and ESCC samples.
|
28365443 |
2017 |
|
Squamous cell carcinoma of esophagus
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The frequency of CCND1 amplification and p16 homozygous deletion is suggested to be associated with ESCC progression.
|
17016592 |
2006 |
|
Squamous cell carcinoma of esophagus
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
There appears to be an influence of CCND1 G870A/G1772C genotypes on genetic susceptibility to ESCC.
|
21268129 |
2011 |
|
Squamous cell carcinoma of esophagus
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
This study aims to analyze the combined prognostic significance of cyclinD1 (CCND1) DNA amplification and the co-alteration of CCND1/pRb/ppRB in patients with esophageal squamous cell carcinoma.
|
22150974 |
2013 |
|
Squamous cell carcinoma of esophagus
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Determination of the cyclin D1 (G870A) single nucleotide polymorphism may be suitable to identify individuals with increased risk for ESCC or CAC in the northern Chinese population.
|
12673692 |
2003 |
|
Squamous cell carcinoma of esophagus
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We investigated whether the putative transforming gene MYEOV, mapping 360 kb centromeric to CCND1 and activated concomitantly with CCND1 in a subset of t(11;14)(q13;q32) positive multiple myeloma cell lines, represents a target of 11q13 amplification in ESC.
|
12202983 |
2002 |
|
Squamous cell carcinoma of esophagus
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
CCND1 and PTEN genetic polymorphisms might induce susceptibility to the occurrence of esophageal squamous cell carcinoma (ESCC).
|
24391010 |
2013 |
|
Squamous cell carcinoma of esophagus
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In this study, we investigated the expression pattern of beta-catenin and cyclin D1 using immunohistochemistry and searched for mutations in exon 3 of the beta-catenin gene and Axin gene in esophageal squamous cell carcinoma.
|
17309796 |
2007 |
|
Squamous cell carcinoma of esophagus
|
0.400 |
Biomarker
|
disease |
BEFREE |
In situ hybridization and immunohistochemistry were used respectively to detect the expression of mRNA and proteins of Egr-1, c-fos and cyclin D1 in 70 cases of esophageal squamous cell carcinoma and their corresponding para-cancerous mucosa and upper cut edge mucosa.
|
14966901 |
2004 |
|
Squamous cell carcinoma of esophagus
|
0.400 |
Biomarker
|
disease |
BEFREE |
In conclusion, LCM coupled with real-time fluorescence quantitative-PCR technique is more precise than PCR for the identifying amplified oncogenes; The role of CCND1 amplification in ESCC development and progression needs more extensive study.
|
17498553 |
2007 |
|
Squamous cell carcinoma of esophagus
|
0.400 |
Biomarker
|
disease |
CTD_human |
Genetic landscape of esophageal squamous cell carcinoma.
|
25151357 |
2014 |
|
Squamous cell carcinoma of esophagus
|
0.400 |
Biomarker
|
disease |
BEFREE |
The purpose of this study was to clarify the relationship of E2F1 and cyclin D1 in ESCC.
|
16053486 |
2005 |
|
Squamous cell carcinoma of esophagus
|
0.400 |
Biomarker
|
disease |
BEFREE |
Using Q-RT-PCR to measure cyclin D1, TS, TP, DPD, and Her-2/neu as predictors for response, survival, and recurrence in patients with esophageal squamous cell carcinoma following radiochemotherapy.
|
18704459 |
2009 |
|
Squamous cell carcinoma of esophagus
|
0.400 |
Biomarker
|
disease |
BEFREE |
CCND1 amplification/overexpression was also significantly correlated with the lymph node metastasis of ESCC.
|
22761904 |
2012 |
|
Squamous cell carcinoma of esophagus
|
0.400 |
Biomarker
|
disease |
BEFREE |
Here we report that entinostat reversed cisplatin resistance in ESCC both in vitro and in vivo by induction of apoptosis and inhibition of cell proliferation, accompanied by a decrease of multidrug resistance gene 1 (MDR1), P-Src, Mcl-1, Cyclin D1 and an increase of cleaved PARP.
|
29107111 |
2018 |
|
Squamous cell carcinoma of esophagus
|
0.400 |
Biomarker
|
disease |
BEFREE |
These genomic catastrophes led to amplification of oncogene through chromothripsis-derived double-minute chromosome formation (e.g., FGFR1 and LETM2) or BFB-affected chromosomes (e.g., CCND1, EGFR, ERBB2, MMPs, and MYC), with approximately 30% of ESCCs harboring BFB-derived CCND1 amplification.
|
26833333 |
2016 |
|
Squamous cell carcinoma of esophagus
|
0.400 |
Biomarker
|
disease |
BEFREE |
Taken together, we propose that LBH589 inhibits ESCC cell proliferation mainly through inducing cell cycle arrest by increasing p21 and decreasing cyclin D1 in a p53-independent manner.
|
30484863 |
2018 |
|
Squamous cell carcinoma of esophagus
|
0.400 |
Biomarker
|
disease |
BEFREE |
Prediction of CCND1 amplification using plasma DNA is thought to be a promising prognostic biomarker in ESCC patients.
|
20389301 |
2010 |
|
Squamous cell carcinoma of esophagus
|
0.400 |
Biomarker
|
disease |
BEFREE |
TAOS1 overexpression was observed in 7 out of 38 (18%) esophageal SCCs and CCND1 overexpression was observed in 4 out of 38 (11%), suggesting that TAOS1 was more frequently overexpressed than CCND1 in esophageal SCC.
|
16827140 |
2006 |
|
Squamous cell carcinoma of esophagus
|
0.400 |
Biomarker
|
disease |
BEFREE |
Influence of apoptosis (BCL2, FAS), cell cycle (CCND1) and growth factor (EGF, EGFR) genetic polymorphisms on survival outcome: an exploratory study in squamous cell esophageal cancer.
|
17912028 |
2007 |
|
Squamous cell carcinoma of esophagus
|
0.400 |
Biomarker
|
disease |
BEFREE |
Moreover, we observed that triptolide induced ESCC cell cycle arrest at the G1/S phase and apoptosis through cyclin D1-CDK4/6 regulation and caspases activation.
|
30779917 |
2019 |
|
Squamous cell carcinoma of esophagus
|
0.400 |
Biomarker
|
disease |
BEFREE |
E2F transcription factor 8 promotes cell proliferation via CCND1/p21 in esophageal squamous cell carcinoma.
|
30532557 |
2018 |
|
Squamous cell carcinoma of esophagus
|
0.400 |
Biomarker
|
disease |
BEFREE |
In this study, we clarified the clinical significance of FBXO31 and characterized the association between cyclin D1 and FBXO31 in ESCC cases.
|
21537837 |
2011 |
|
Squamous cell carcinoma of esophagus
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our findings reveal a molecular basis for cancer therapy through targeting glutaminolysis and mitochondrial respiration in ESCC with dysregulated Fbxo4-cyclin D1 axis as well as cancers resistant to CDK4/6 inhibitors.
|
30899002 |
2019 |
|
Squamous cell carcinoma of esophagus
|
0.400 |
Biomarker
|
disease |
BEFREE |
Seventeen (34%) of the 50 ESCC primary lesions were cyclin D1-positive, while 33 (66%) were cyclin D1-negative.
|
11295092 |
2001 |